Obesity & Diabetes Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Diabetes Therapy

Cardiovascular effects of rosiglitazone reviewed

According to published research from France, "Since their launch on the French market in 2002, thiazolidinediones ('glitazones') prescribing conditions and therapeutic indications have progressively widened, although remaining strictly defined by the marketing license. Clinical efficacy on glycemic control (HbA_1c and glycemia), as well as beneficial metabolic effects (on lipids, insulin resistance, and beta-cellular function) are now well established. Their side effects, generally minor or mild, are also well known."

"The problem of...

• View Other Issues of Obesity & Diabetes Week
  
• View Other NewsRx Publications